

US EPA ARCHIVE DOCUMENT

National Cancer Institute



**MICHAEL ALAVANJA, DR.P.H.**  
SENIOR INVESTIGATOR  
OCCUPATIONAL & ENVIRONMENTAL EPIDEMIOLOGY  
BRANCH, DCEG, NCI

OCTOBER 11, 2011, BIOMARKERS IN PESTICIDE,  
SURVEILLANCE, AND EPIDEMIOLOGY RESEARCH

21<sup>ST</sup> CENTURY TOXICOLOGY STATE HOLDER WORKSHOP.

# Agenda

- 1) Introduction
  - Background and design of the AHS
- 2) Cancer epidemiology/biomarker studies
  - e.g., multiple myeloma, prostate cancer
- 3) Exposure assessment in the AHS

# 1. Introduction

1992

- Concept for the Agricultural Health Study presented to NCI peer review

1993

- Field Work Began December 13, 1993

1993

- Cancer Incidence and Mortality Monitoring: 1993-2008


## *Goal of Research Program:*

- ▣ Identify human carcinogens among 80 active ingredients in pesticide formulations used occupationally by hundreds of million people world-wide.

# Background

- ❑ Only 1 pesticide (arsenical insecticides) and 1 pesticide contaminant (dioxin) are classified as Human Carcinogens by IARC, although many others are suspected carcinogens.
- ❑ Previous health studies characterized as having inadequate exposure assessment, reducing our ability to identify agents responsible for disease (Zahm et al., 1997, Kromhout and Heedrick 2005).
- ❑ Case-control studies (case-recall bias)
- ❑ Factory-based pesticide studies—frequently too small to assess individual pesticides for cancer.

# Causal Logic to Establish Human Carcinogenicity



# Agricultural Health Study (AHS) Design

- Prospective (exposures assessed prior to cancer onset):
  - 52,000 private applicators (i.e., farmers)
  - 32,000 spouses of farmers
  - 5,000 commercial applicators
- Two important agricultural states (Iowa & North Carolina)
  - Corn, soybean and hog production in both states
  - Distinctive agriculture in North Carolina: fruits, vegetables, tobacco, cotton



# AHS Design

- ▣ Little loss to cancer incidence follow-up (<2 %)
  - Population-based cancer registries in both states
  - Determine if study subjects move from state (IRS records)
  - National Death Index (NDI)-no loss to mortality follow-up
  
- ▣ Over one-million person-years of follow-up

## 2. Cancer Epidemiology/Biomarker Studies

2002

- AHS Exposure Algorithm (Dosemeci et al., Annals of Ind. Hygiene; 46:245-260)

2003

- First Nested Case-Control Study: Prostate Cancer (Alavanja et al., AJE; 157:800-814)

2004

- First Cohort Analysis: Alachlor (Lee W et al., AJE; 159:378-830)

### *Goals of Research Program:*

- ▣ Identify human carcinogens among 80 active ingredients in pesticide formulations used occupationally by hundreds of millions of people world-wide.
  - Establish Exposure Algorithm
  - Nested Case-Control Analyses (N=5)
  - Follow-up Cohort Analyses ( N=27)
  - Biomarker Studies

# Multiple Myeloma (MM)

2005

- MM SIR= 1.34 (0.97-1.81) (Alavanja et al., Scand J Work Environ; 31;39-45)

2009

- MGUS 2-fold excess in AHS (Landgren et al., Blood; 113: 6386-6391)

2010

- Initiated Biomarker Study (BEEA) (Alavanja et al.)

## *Specific Aims:*

- ▣ Identify pesticides that may be responsible for the excess MM risk in the AHS.
- ▣ Identify pesticides and other occupational exposures etiologically linked to monoclonal gammopathy of undetermined significance (MGUS), a confirmed precursor of MM.

# Multiple Myeloma (MM)

- A largely incurable neoplasm of plasma cells characterized by an overproduction of monoclonal immunoglobulins
- Etiology not well understood, occurs in excess among farmers (Milham S, Am J Epidem 1971, 94(4):507-510)
- MM is highly fatal

## MGUS Precedes Multiple Myeloma (MM): in a Prospective Study (PLCO)

- ▣ MGUS ----> MM
  - ▣ MM always preceded by a premalignant disorder MGUS [monoclonal gammopathy of undetermined significance]. (Landgren O et al., *Blood* 2009;113:5412-5417)

## Risk of MGUS in AHS vs. Olmstead County, MN

Population	Total, n	MGUS, n	OR (95% CI)
Olmstead County	9,469	350	1.0 (ref)
AHS cohort	555	38	1.9 (1.3-2.7)

-Landgren O et al., Blood (2009); 113(25):6386-6391

-Protein Immunology Laboratory at Mayo Clinic, Rochester, Minnesota  
(Robert Kyle, Jerry Katzmann, Vincent Rajkumar)

## Specific Pesticide Use at Enrollment and Risk of MGUS in 2008 Among 679 Male Applicators in the AHS

Pesticide	Exposed	Total n	Exposed n	OR (95% CI)
Dieldrin	Never	649	31	1.0 (ref)
	Ever	20	6	5.6 (1.9-16.6)
Carbon tetrachloride/ Carbon disulfide mix	Never	632	31	1.0 (ref)
	Ever	41	7	3.9 (1.5-10.0)
Chlorothalonil	Never	649	31	1.0 (ref)
	Ever	20	6	2.4 (1.1-5.3)

-Landgren O et al., Blood (2009); 113(25):6386-6391

-Protein Immunology Laboratory at Mayo Clinic, Rochester, Minnesota  
(Robert Kyle, Jerry Katzmann, Vincent Rajkumar)

## Permethrin Use at Enrollment and Risk of Multiple Myeloma in the AHS

Tertile	Intensity-Weighted Lifetime Exposure-Days			
	No	RR	(95% CI)	<i>p</i> -trend
0	29	1.0 (ref.)		
1	2	0.92	(0.22-3.85)	
2	3	1.55	(0.47-5.12)	
3	10	5.01	(2.41-10.42)	<0.01

-Rusiecki et al., Environ Health Perspect (2009); 117(4):581-586

# Current Research for MM

- ▣ Initiated the Biomarkers of Exposure and Effect in Agriculture study (*Alavanja et al., BEEA Study, 2010*)
  - 1,600 AHS study subjects will donate blood and urine samples (2010-2014)
  - Biomarker questionnaire to assess current exposures

## Potential Future Work on BEEA: Other Biomarkers of Potential Interest

- ▣ Measure monoclonal B-cell lymphocytosis (MBL)
- ▣ Measures of oxidative stress
- ▣ Measures of epigenetic changes
- ▣ Markers of immune perturbation
- ▣ Chromosomal aberrations
- ▣ Other biomarkers as appropriate

# Prostate Cancer

2003

- Nested Case-Control (Alavanja et al., AJE; 157:800-814)

2006

- Initiated G X E Study
- iSelect Platform; NCI Core Genotyping Facility

2010

- 8q24 Interaction with Fonofos (Koutros et al., Can Res. 70:9221-9233)
- Other Pathways

## *Specific aims:*

- ▣ Identify pesticide exposures that may be responsible for the excess prostate cancer risk in the AHS cohort.
- ▣ Identify markers of susceptibility that may be associated with prostate cancer etiology in the AHS cohort.

## Nested Case-Control Study

(Alavanja et al., AJE 2003, 157:800-814)

Prostate cancer risk (Significant interaction with family history PC):

- ▣ Fonofos
- ▣ Coumaphos
- ▣ Phorate
- ▣ Permethrin
- ▣ Butylate

- 
- ▣ Terbufos (Near significant interaction with family history of PC)

# Risk of Prostate Cancer by Fonofos Exposure With and Without a Family History of Prostate Cancer in the AHS

Pesticide	PC risk, no family history of PC			PC risk, family history of PC			Statistical interaction, PC history & Pesticide Exposure
	Odds Ratio	95% C.I.	Cases	Odds Ratio	95% C.I.	Cases	
Lifetime exposure days							
0	1.00	Ref.	534	1.00	Ref.	100	
>0-20	1.08	0.82-1.41	58	1.42	0.84-2.41	16	1.28 (1.07-1.54)
>20-56	0.93	0.70-1.35	51	1.57	0.95-2.60	18	
>56	0.86	0.60-1.24	30	1.77	1.03-3.05	15	
P trend	P=0.37			P=0.02			

Mahajan R et al. Environ Health Perspecti (2006); 114 (12): 1838-1842

## Case-Control Study of Prostate Cancer; Gene- by-Environment Interaction

### Chromosome 8q24 , fonofos exposure and prostate cancer risk

	No fonofos exposure	Low fonofos exposure	High fonofos exposure
Odds Ratio	1.17	1.30	4.46
95% C.I.	0.93-1.48	0.75-2.27	2.17-9.17

- Koutros, et al., Cancer Research 2010; 70(22):9224-9233
- previously identified variant rs4242382
- adjusted *P*-interaction=0.02
- 776 cases + 1,444 controls

## Case-Control Study of Prostate Cancer; Gene- by-Environment Interaction (continued)

### Chromosome 8q24 , terbufos exposure and prostate cancer risk

	No terbufos exposure	Low terbufos exposure	High terbufos exposure
Odds Ratio	1.13	1.71	2.15
95% C.I.	0.87-1.47	1.07-2.74	1.32-3.52

-Koutros, et al., Cancer Research 2010; 70(22):9224-9233

-previously identified variant rs4242382

-adjusted *P*-interaction=0.02

-similar effect modification for fonofos, coumaphos, phorate, permethrin

-fonofos, phorate and terbufos are phosphorodithioates

# Future/Current Biomarker work in this Case- Control Study

- ▣ Susceptibility genes (*replication necessary*):
  - Base-excision repair (BER)- [Hughes Barry et al.](#)
  - Nucleotide excision repair (NER)- [Hughes Barry et al.](#)
  - Xenobiotic metabolizing enzymes (XME)-[Koutros et al.](#)
  - Others genes/pathways from prostate etiology literature
- ▣ Telomere length- [Hou, et al., ongoing](#)
- ▣ Epigenetics- [Hou,et al., ongoing](#)

### 3. Exposure Assessment in AHS

2002

- AHS Exposure Algorithm (Dosemeci et al., Annals of Ind Hygiene; 46:245-260).

2010

- Assessment of Algorithm (Thomas et al., J Exp Sci Env Epidemiol; 20:193-134)

2010

- Assessment of Algorithm (Coble et al., Submitted)

*Specific aims:*

- ▣ Optimize questionnaire-based exposure assessment by improving the exposure algorithm

# Intensity Weighted Exposure Days

Intensity Weighted Exposure Days=

Total Days of Specific Pesticide Use  $\times$  Intensity  
Score

# AHS Exposure Assessment Algorithm

Intensity Score=

$$(\text{Mix} + \text{Application Method} + \text{Repair}) * \text{PPE}$$


Dosemeci M et al. (2002) Ann Occup Hyg; 1 46 (2); 245-260.

# AHS Algorithm Intensity Score Evaluation

Algorithm intensity scores from observations and an interviewer administered questionnaire and correlation between scores

	Observation		Questionnaire		Spearman	
	Mean ±SD	Range	Mean ±SD	Range	r	P-value
2,4-D	9.9 ±4.5	1.8-20	10.3 ±4.6	3.0-20.0	0.92	<0.001
Chlorpyrifos	9.2 ±2.4	4.4-14	9.4 ±2.6	6.6-14	0.84	<0.001

Thomas et al.; J Exposure Science and Environ Epidem; 2010;20(6):559-569



Distributions of Day-1 post-application urinary 2,4-D concentrations across three “tertiles” of algorithm intensity scores (\*geometric mean [GM] values for low and medium groups are significantly different from the GM in the high group).

# Future Cancer Etiology in AHS

- ▣ Reevaluate approximately 30 pesticides for various cancers- e.g., atrazine-Beane Freeman et al.
- ▣ Evaluate less frequently used pesticides in AHS
- ▣ Evaluate cancers of lower frequency (e.g., leukemia, NHL)
- ▣ Biomarkers of Exposure and Effect in Agriculture (BEEA)
  - MGUS
  - MBL
  - Other
  - Expand the Study
- ▣ G X E Analysis for Prostate Cancer
- ▣ Environmental Cancer Risk —(e.g., Dr. Ward: drinking water, Dr. Beane Freeman: endotoxin)

# Intramural Research Team

- **National Cancer Institute:**
  - Michael Alavanja Co-PI
  - Laura Beane Freeman Co-PI
  - Mary Ward
  - Sonja Berndt
  - Stella Koutros
  - Gabriella Andreotti
  - Jonathan Hofmann
  - Neil Caporaso
  - Ola Lundgren
  - Sharon Savage
  - Rashmi Sinha
  - Jay Lubin
  - Aaron Blair
  - Shelia Zahm
  - Kathryn Hughes Barry
  - Curt Dellavalle
- **NIOSH**
  - Cynthia Hines Co- PI
  - Brian Curwin
  - Paul Henneberger
  - Greg Kullman
- **NIEHS**
  - Jane Hoppin Co-PI
  - Dale Sandler Co-PI
  - Freya Kamel
  - Donna Baird
  - Olga Basso
  - Stephanie London
  - Beth Regan
  - David Umbach
  - Clarice Weinberg
  - Martha Montgomery
  - Sharon Myers
  - Tina Saldana
  - Martin Valcin
  - Jenna Waggoner
- **USEPA**
  - Kent Thomas CO-PI
  - Carol Christensen

**Thank you.**

➤ **Questions?**